Senior Vice President, Chief Financial Officer · CytomX Therapeutics, Inc. (CTMX)

Carlos Campoy

A named executive officer of CytomX Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,396,204

Salary $477,555Stock awards $160,200

FY2020: $1,741,639

5th of 5 named executive officers at CytomX Therapeutics by FY2021 total.

5 named officers on file for CytomX Therapeutics, FY2021

Carlos Campoy’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • CTMX’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how CytomX Therapeutics’s whole pay program stands against its peers

  • CytomX Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CTMX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2022 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Carlos Campoy’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Carlos Campoy compensation by year

CytomX Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as CytomX Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$360,052$477,555
Bonus$0$0
Stock awards$0$160,200
Option awards$972,860$557,652
Non-equity incentive$144,723$195,797
Pension and deferred compensation$0$0
All other$264,004$5,000
Total$1,741,639$1,396,204

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CytomX Therapeutics, Inc. DEF 14A filed April 27, 2022, accession 0001140361-22-016242, and prior-year filings. Open the filing on EDGAR.

How this page was built: the CytomX Therapeutics, Inc. filed document, accession 0001140361-22-016242. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2022.

$1.7M
$1.4M
FY20
FY21
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option38,334—$5.34
Option196,875—$4.93
Option79,167—$7.85

Per the Outstanding Equity Awards at Fiscal Year-End table in CytomX Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

1 Form 4 line since the FY2021 proxy (filed April 27, 2022)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2023-03-16Sale—1,748$1.9838,224

The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

CytomX Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
D. Sean A. McCarthyChief Executive Officer and Chairman of the Board of Directors$4,339,415
Amy PetersonPresident, Chief Operating Officer$2,252,280
Alison HannahSenior Vice President and Chief Medical Officer$1,707,176
Lloyd RowlandSenior Vice President, General Counsel, Chief Compliance Officer and Secretary$1,421,758
Carlos Campoy · this pageSenior Vice President, Chief Financial Officer$1,396,204

The full CytomX Therapeutics compensation record

free company brief

This page is one person within CytomX Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the CytomX Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CytomX Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Carlos Campoy's compensation dossier · One-time report. No refunds.